Cashu Research
Deep-dive equity research on the most compelling small caps in mining and biotech. Join 60,000+ investors, brokers and institutions.
Market insights and full research reports from Cashu Research, newest first.
PPIH trades at 8.4× EV/EBITDA, below its listed peers. Growth and a US$42.10 model target support the case, but receivables and execution remain key risks.
MRD's 94.9% gallium result adds evidence to the third-party processing opportunity in our latest research. We explain what it changes, why it is not a valuation upgrade and the next milestones.
Cheap drones have changed modern warfare. Canberra-based Boresight (ASX: BST) is building a business around a practical response: giving defence forces realistic targets to train against.
Arrow trades at 2.2 times EV/EBITDA in our October research. We look at production growth, Thorsby and the Tapir contract risks behind the discount.
Selectro's first third-party feed test returned 91.9% aluminium and 96.7% iron extraction from ASQ bauxite, addressing a milestone identified in our recent MRD research. Commercial proof remains ahead.
A year after our SELL call, Life360's share-price reference is roughly 64% lower, even as operating results beat our forecasts. We revisit what held up, what we overstated and why valuation mattered.
MRD's 91.8% laboratory recovery raises a bigger question: could Selectro support a viable Western processing route? We examine the peer comparison, SRL's conditional financing and Grass Patch's resource growth.
Global shipping has been buffeted by route disruption, volatile rates and port-cost uncertainty. Yet Global Ship Lease has $3.20bn in contracted revenue. Is the market pricing in too much risk?
Phase 2 re-assays identify shallow scandium mineralisation beyond the expanded Block 1 and 2 resource boundaries, with further resource modelling and a third re-assay phase planned.
Selectro Test 3 lifted scandium recovery to 91.8% and averaged 84% heavy rare earth recovery while halving the reagent dose. We reiterate our Speculative Buy rating and maintain our A$0.144 price target.
Selectro Test 3 lifted scandium recovery to 91.8% and average heavy rare earth recovery to 84% on unbeneficiated Grass Patch material, despite halving the reagent dose.
K2 Gold is drilling a permitted and fully funded 14,000m program into a high-grade oxide-gold system at Mojave in California. We initiate with a Speculative Buy rating and C$1.25 price target, while recognising the absence of a resource, unknown true widths and untested metallurgy.
